Original Article

Hemifacial spasm: 20-year surgical experience, lesson learned

Hector Soriano-Baron, Olivia Vales-Hidalgo¹, Emiliano Arvizu-Saldana², Sergio Moreno-Jimenez¹, Rogelio Revuelta-Gutierrez¹

Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, U.S.A., ¹Division of Neurological Surgery, National Institute of Neurology and Neurosurgery, Manuel Velasco Suarez, Mexico City, ²Division of Neurological Surgery, Hospital Medica Tec100, Queretaro, Mexico

E-mail: Hector Soriano-Baron - neuropub@dignityhealth.org; Olivia Vales-Hidalgo - valpooli@gmail.com; Emiliano Arvizu-Saldana - neuropub@dignityhealth.org; Sergio Moreno-Jimenez - radioneurocirugia@gmail.com; *Rogelio Revuelta-Gutierrez - rogelio7revuelta@gmail.com

*Corresponding author

Received: 14 January 15  Accepted: 02 March 15  Published: 20 May 15

This article may be cited as:
Soriano-Baron H, Vales-Hidalgo O, Arvizu-Saldana E, Moreno-Jimenez S, Revuelta-Gutierrez R. Hemifacial spasm: 20-year surgical experience, lesson learned. Surg Neurol Int 2015;6:83.
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2015/6/1/83/157443

Abstract

Background: Hemifacial spasm is characterized by unilateral, paroxysmal, and involuntary contractions. It is more common in women on the left side. Its evolution is progressive, and it rarely improves without treatment.

Methods: Microvascular decompressions (N = 226) were performed in 194 Hispanic patients (May 1992–May 2011). Outcomes were evaluated on a 4-point scale: Excellent (complete remission); good (1–2 spasms/day); bad (>2 spasms/day); and recurrence (relapse after initial excellent/good response).

Results: Most patients were female (n = 123); 71 were male. Mean (±SD) age was 49.4 (±11.7) years; age at onset, 43.9 (±11.9) years; time to surgery, 5.7 (±4.7) years. The left side was affected in 114 patients. Typical syndrome occurred in 177 (91.2%); atypical in 17 (8.8%). Findings were primarily vascular compression (n = 185 patients): Anterior inferior cerebellar artery (n = 147), posterior inferior cerebellar artery (n = 12), basilar artery (n = 10), superior cerebellar artery (n = 8), and 2 vessels (n = 8); 9 had no compression. Postsurgical results were primarily excellent (79.9% [n = 155]; good, 4.6% [n = 9]; bad, 15.5% [n = 30]), with recurrence in 21 (10.8%) at mean 51-month (range, 1–133 months) follow-up. Complications included transient hearing loss and facial palsy.

Conclusions: The anterior inferior cerebellar artery is involved in most cases of hemifacial spasm. Failure to improve postsurgically after 1 week warrants reoperation. Sex, side, and onset are unrelated to treatment response. Microvascular decompression is the preferred treatment. It is minimally invasive, nondestructive, and achieves the best long-term results, with minor morbidity. To our knowledge, this series is the largest to date on a Hispanic population.

Key Words: Cerebellopontine angle, facial nerve, facial tic, hemifacial spasm, microvascular decompression

INTRODUCTION

Hemifacial spasm (HFS) is an overactive facial nerve dysfunction syndrome with spontaneous and gradual onset characterized by unilateral, clonic, paroxysmal, and involuntary contractions of one or more facial muscles innervated by the same facial nerve. In general, contractions occur spontaneously or are elicited...
by emotional stress, fatigue, or volitional movements of the face; contractions decrease during rest but may persist during sleep.\textsuperscript{12,61}

HFS occurs almost exclusively in adults.\textsuperscript{28,34} It is not hereditary, although some familial cases have been described.\textsuperscript{7,14,36} HFS occurs slightly more often in women, typically on the left side. In rare cases, it is bilateral, but not symmetrical or synchronous.\textsuperscript{27,61}

In general, HFS becomes worse over time.\textsuperscript{3,11,61} Untreated, it can be associated with mild ipsilateral facial paralysis\textsuperscript{11,33} or trigeminal neuralgia (i.e. tic convulsif \cite{tic convulsive},\textsuperscript{8} as first described by Cushing).\textsuperscript{8,9,46}

The pathogenesis of HFS is not fully understood.\textsuperscript{52} HFS is associated with compression of the facial nerve by a vascular loop at the entry point of the nerve root at the brainstem [Figure 1].\textsuperscript{16,15,24,32,54} Some theories support a hyperexcitability of the facial motor nucleus in the brainstem\textsuperscript{6,40} and psychosomatic factors.\textsuperscript{46}

The diagnosis of HFS is clinical.\textsuperscript{18,37} Although electrophysiology (electromyography) can be useful. Imaging studies, such as computed tomography, magnetic resonance imaging, and angiography, do not help establish the diagnosis but are useful in identifying associated pathology.\textsuperscript{10,17,41,36-38}

Response is poor to medication therapy (e.g. carbamazepine, gabapentin).\textsuperscript{15,16,39,51} Botulinum toxin type A is temporarily useful (transient improvement of 90–100%), but it requires repeat and frequent administration of injections; side effects include ptosis, keratitis, and diplopia.\textsuperscript{18,55} Currently, the best long-term control is achieved through microvascular decompression, first postulated by Gardner\textsuperscript{15} and then popularized by Jannetta and colleagues.\textsuperscript{8,24-26,28,59} Continued improvement in surgical techniques has allowed surgeons to perform decompression with a minimally invasive approach.\textsuperscript{19,46,47,79}

The aim of this study was to analyze the demographics, clinical manifestations, outcomes, and complications of patients who underwent microvascular decompression of the facial nerve for the treatment of HFS at the National Institute of Neurology and Neurosurgery, Manuel Velasco Suárez, Mexico City, Mexico, between May 1, 1992, and May 31, 2011.\textsuperscript{46}

\section*{MATERIALS AND METHODS}

A total of 194 patients were diagnosed with HFS and surgically treated with microvascular decompression through a posterior fossa craniectomy by the senior author (R. R.-G.). A retrospective analysis was performed of the medical records of all patients to abstract sex, age, clinical history, evolution, previous treatment, preoperative imaging (computed tomography and/or magnetic resonance imaging), surgical findings, complications, outcomes, and response to treatment. Postsurgical follow-up was performed with postoperative clinic visits. This study was approved by the Institutional Review Board of the National Institute of Neurology and Neurosurgery.

Postoperative results and follow-up findings were evaluated by the following criteria: (i) excellent: Complete remission of HFS (defined as 2 muscle spasms per week); (ii) good: 1 or 2 muscle spasms per day, with remarkable improvement from the preoperative state; (iii) bad: More than 2 muscle spasms per day, with slight improvement or status unchanged after surgery; and (iv) recurrence: Relapse of symptoms after initial excellent or good response.

Statistical analysis (counts, percentages, mean [SD], Fisher’s exact test, and the Chi-square test) was conducted using SPSS statistical software (IBM Corp). Significance was defined as $P = 0.05$.

\section*{RESULTS}

A total of 226 microvascular decompressions were performed (194 first surgeries; 32 reinterventions) in 194 patients with HFS during the period of analysis.

\subsection*{Demographic findings}

In this series of 194 patients, most were women ($n = 123$ [63.4%]); 71 were men (36.6%). The left side was affected in 114 patients (58.8%), the right side in 80 (41.2%). Patients ranged in age from 19 to 76 years (mean [$\pm$SD], 49.4 [$\pm$11.7] years). The mean ($\pm$SD [range]) age of onset was 43.9 years ($\pm$11.9 [range, 3–70] years), and the time to surgery was 5.7 years ($\pm$4.7 [1–50] years).

There was only one case of bilateral HFS. This patient had an intervening span of 5 years before occurrence in the second side.
Clinical findings
By type of clinical onset, patients were classified into two groups: Typical syndrome and atypical syndrome. Typical HFS syndrome (onset in the upper hemiface, usually the lower eyelid, which progressed downward to affect the cheek and oral commissure) occurred in 177 patients (91.2%). Atypical syndrome (first affecting muscles of the mouth, then gradually spreading upward to the cheek and eyelid) occurred in 17 patients (8.8%). Two patients (1.0%) had tic convulsive.

Prior to surgery, pharmacological therapy (e.g., carbamazepine, benzodiazepine) was used, with poor response, in 108 patients (55.7%). Nineteen patients previously treated with botulinum toxin type A injections had satisfactory temporary results lasting 4–6 months in most cases. One patient underwent microvascular decompression at another institution without postoperative clinical improvement.

Preoperatively, all patients underwent audiological evaluation. Thirty-one patients had abnormal results on an auditory evoked potential test that suggested vascular compression; 28 patients were found to have ipsilateral nonuseful hearing; and the rest of the patients (n = 135) had a normal test. Four patients had tinnitus, 13 had facial hypoesthesia, and 13 had mild facial paralysis (House–Brackmann score < 3).

Preoperative imaging (computed tomography and/or magnetic resonance imaging) showed no anomalies in 112 patients. Fifty-two patients had a vascular loop compressing the facial nerve root at its entry point at the brainstem, and 30 patients had basilar artery ectasia.

Surgical findings
All 194 patients underwent surgery for vascular decompression of the entry point of the facial nerve root at the brainstem. An operative microscope and microsurgical instruments were used, with the patient in the park-bench position. The first 18 procedures were approached through a lateral suboccipital craniectomy, and the subsequent 176 were accessed via a retrosigmoid asterional craniectomy (maximum diameter, 20–25 mm). In two patients, endoscopy was used to facilitate the procedure.

Vascular compression was identified in 185 patients. Nine patients showed no compression. In the 185 patients with vascular compression, the nerve root was isolated from the offending vessel by placing nonabsorbable material (Dacron [polyethylene terephthalate fiber] in 10 patients, Silastic [silicone rubber] in 15 patients, and Teflon [polytetrafluoroethylene] in 169 patients). Teflon was the preferred material because of its maneuverability and ease of use. In nine patients with no evidence of vascular compression, the surgeon performed compression of the facial nerve root to alleviate HFS.

The most commonly identified offending vessel was the anterior inferior cerebellar artery (AICA) (n = 147 patients [75.8%]), followed by the posterior inferior cerebellar artery (PICA) (n = 12 [6.2%]), the basilar artery (n = 10 [5.2%]), and the superior cerebellar artery (n = 8 [4.1%]). More than one vessel (AICA and basilar artery) was involved in eight patients (4.1%), and no identifiable offending vessel was found in nine patients (4.6%).

Postoperative outcomes
After the first surgery, all conservative treatment was discontinued. The 4-point outcomes scale identified excellent results in 155 patients (79.9%), good results in 9 (4.6%), and bad results in 30 (15.5%). Of the 30 patients with bad results, 1 died after the first surgery. The remaining 29 patients underwent a reintervention using the same approach within a period of 2–7 days postoperatively. No additional vascular compression or other factors were evident that could explain the lack of response. Compression of the facial nerve root was therefore performed in all 29 patients, with excellent results in 26 patients and bad results in 3 patients who required a third surgery that resulted in excellent outcomes for all 3, for a total of 226 surgeries in 194 patients. During follow-up, 21 other patients (10.8%) had recurrence after initial surgery within 2 months to 3 years after surgery but declined additional surgeries.

Complications
Complications included paresis (House–Brackman score < 3) in 34 patients, with onset on postoperative day 1, with improvement during the first month of follow-up in 28 patients (mean, 4.5 days [range, 1–30 days]). Marked hearing loss developed in 29 patients, 10 of whom fully recovered postoperatively in the first month, and 19 of whom continued to have nonuseful hearing by audiometry at 6-month follow-up. Tinnitus was present in four patients, three of whom had complete resolution at 1-month follow-up. Other complications are summarized in Table 1.

DISCUSSION
HFS is a relatively rare entity that occurs most commonly in middle-aged women. According to Auger and Whisnant,[6] HFS has an incidence of 0.8 cases per 100,000 persons, with a mean prevalence of 7.4 cases per 100,000 men and 14.5 per 100,000 women. Typical symptoms begin with intermittent contractions of the lower orbicular muscle, most commonly on the left side, which tend to extend ventrally to the rest of the ipsilateral facial muscles.[26] Although HFS is not painful, the associated stress it elicits interferes with activities of daily living, such as work, reading, and driving.[35,99] The affected patients in our study were in the fifth and sixth decades
of life, with a slight preponderance of women (63.4%) and with occurrence on the left side of the face (58.8%), consistent with results reported in the current medical literature.\textsuperscript{[15,24,27]} Some studies of Asian populations have shown a predominance in men and occurrence on the right side.\textsuperscript{[20,54]} Other signs or symptoms are not common; the incidence of associated facial paralysis has been reported in 10–57% of cases.\textsuperscript{[3,6,20,64]} However, we observed a lower incidence (6.7%) in our series.

The pathogenesis of HFS, as described by Jannetta and colleagues,\textsuperscript{[6,5,10,15,24,28,40,41,54]} Moller\textsuperscript{[40]} and Shin et al.\textsuperscript{[54]} is believed to be secondary to neurovascular compression of the root of cranial nerve VII at its entry zone (at the transition between the central myelin and the peripheral myelin). This theory is widely accepted and recognized, but is also highly disputed.

The diagnosis of HFS is clinical; electrophysiology and imaging studies are required to assess other pathologies of the cerebellopontine angle. In our study, no patients had associated tumors, aneurysms, arteriovenous malformations, arachnoid cysts, gliomas, brainstem strokes, or multiple sclerosis, which have been reported in previous studies of HFS.\textsuperscript{[17,43,56-58]} Differential diagnoses may include facial tic, postparalytic HFS, habitual spasm, facial myokymia, partial continuous epilepsy, essential blepharospasm, late dyskinesia, oromandibular dystonia, masticatory spasm, and Meige syndrome.\textsuperscript{[3,51]}

Therapeutic options include medication, botulinum toxin type A injections, and surgical decompression. The most commonly used medications are carbamazepine, phenytoin, baclofen, and clonazepam.\textsuperscript{[1,5,16,39,41,50,53]} Subcutaneous injection of affected muscles with botulinum toxin type A produces complete or almost complete relief of symptoms in most (90–100%) patients. However, the improvement is only temporary (mean duration, 3–6 months), and periodic repeat dosing is required. In addition, botulinum toxin type A has been associated with multiple side effects, such as ptosis, keratitis, and diplopia.\textsuperscript{[38,53]} Microvascular decompression produces decreased interstitial resistance and allows myelin regrowth on affected fibers.\textsuperscript{[45,53]} The immediate relief of spasms can result from disappearance of the spontaneous or ectopic excitation caused by pulsating compression of the offending vessel.\textsuperscript{[40,41,45,46]} This improvement can result from the complete microstructural regeneration of the nerve or from the gradual stabilization of the facial motor nucleus.\textsuperscript{[40,59]}

In our series, the most commonly offending vessel was the AICA (75.8%). Other affected vessels were the PICA (6.2%), the basilar artery (5.2%), and the superior cerebellar artery (4.1%). Similar findings have been reported by Wilson et al.\textsuperscript{[60]} (AICA 54.4%), Fairholm et al.\textsuperscript{[11]} (AICA 66.6%), and Samii et al.\textsuperscript{[51]} (AICA 54.5%), contrary to the findings of Barker et al.\textsuperscript{[6,32]} and Loeser and Chen,\textsuperscript{[6,33]} who found more cases of PICA.

Reports of complete cessation of spasms document success rates of more than 50%, from lows of 60% (Loeser and Chen\textsuperscript{[53]}), 63% (Kaye and Adams\textsuperscript{[29]}), 64% (Neagoy and Dohn\textsuperscript{[44]}), and 67% (Rushworth and Smith\textsuperscript{[49]}), to highs of 78% (Farbiniy and Adams\textsuperscript{[12]}), 80% (Rhoton\textsuperscript{[40]}), 82% (Wilson et al.\textsuperscript{[60]}), 85% (Auger\textsuperscript{[21]}), and 93% (Jho and Jannetta).\textsuperscript{[28]} We observed excellent results in 79.9%, good results in 4.6%, bad results in 15.5%, and recurrence in 10.8%. Sex, side, and onset were not statistically correlated with outcome [Table 2]. The reasons for recurrence and clinical failure after surgery are debatable.\textsuperscript{[5,34,59]} In some cases, an additional vessel can be identified; in others, there may be preoperative neuronal damage, perineural scar formation and/or arachnoid adhesions, indirect compression by the material used for decompression, or indirect compression by cerebrospinal fluid.\textsuperscript{[31]} Current reports document a variable failure rate after a first surgery that ranges from lows of less than 15% (11.9% [Illingworth et al.\textsuperscript{[21]}], 13.0% [Huang et al.\textsuperscript{[20]}], 13.0% [Kim and Fukushima\textsuperscript{[10]}], and 13.6% [Iwakuma et al.\textsuperscript{[21]}]) to 33.5% (Fukushima et al.\textsuperscript{[54]}), to highs of 78% (Farbiniy and Adams\textsuperscript{[12]}), 80% (Rhoton\textsuperscript{[40]}), 82% (Wilson et al.\textsuperscript{[60]}), 85% (Auger\textsuperscript{[21]}), and 93% (Jho and Jannetta).\textsuperscript{[28]}

| Variable | Extent of cessation, No. (%) | P value |
|----------|----------------------------|---------|
|          | Complete                   | Partial |
| Sex      |                           |         |
| Female   | 105 (54.1)                 | 18 (9.3) |
| Male     | 58 (30.0)                  | 13 (6.7) |
| Side     |                           |         |
| Right    | 65 (33.5)                  | 15 (7.7) |
| Left     | 98 (50.5)                  | 16 (8.2) |
| Onset    |                           |         |
| Typical  | 148 (76.3)                 | 29 (14.9) |
| Atypical | 15 (7.7)                   | 2 (1.0)  |

\textsuperscript{aPercentages total >100% due to rounding.}

\textsuperscript{bPercentages total >100% due to rounding.}
highs of 22.7% (Augur), 36.4% (Shin et al.), and 50.3% (Ishikawa et al.). In our series of 194 patients, 30 patients (15.5%) had bad results (including 1 death) after the first surgery, which is comparable with outcomes of other studies. Twenty-nine patients then underwent a second surgery, and 26 had excellent results, similar to outcomes of Barker et al.

Ishikawa and colleagues reported that patients with recurrent symptoms in the first 4 days after surgery require immediate exploration, and those with later recurrence without facial paresis are likely to improve within the next 8 months to 2 years. Twenty-one of our 194 patients had recurrence; none of them were taken to reexploration either because the patients did not approve an additional surgery or because they were still under surveillance (2 years after surgery) at the time of this review.

In our study, the rate of permanent deficits was similar to those reported by Barker et al., Shin et al., and Loeser and Chen. The most common complications were transient facial paresis and permanent hearing deficit, especially after reintervention, and these can be explained by the increased neural tissue manipulation or the presence of scar tissue.

**CONCLUSIONS**

Limitations of this study include those inherent to its retrospective nature and its inclusion of only a Hispanic population. Nonetheless, to our knowledge, this is the largest series to date on HFS in a Hispanic population. Previous reports have not analyzed the unique features of HFS in this population, which makes this study relevant to address the lack of knowledge in the field.

Additional studies are needed to fully understand the nature of HFS, the response of patients to different treatment options, and the development of recurrence. So far, microvascular decompression offers the best long-term outcome for treatment of HFS, with low morbidity and mortality. Ongoing improvements in surgical techniques allow microvascular decompression to be performed through a minimally invasive approach. The most commonly implicated vessel is the AICA. Postoperative complications may be related to the experience of the surgeon, the necessity for reoperation, and the use of a refined surgical technique. Factors related to nonresponse or recurrence remain unknown. However, if surgery does not relieve the spasm during the first week, we recommend immediate reexploration.

**REFERENCES**

1. Alexander GE, Moses H 3rd. Carbamazepine for hemifacial spasm. Neurology 1982;32:286-7.
2. Auger RG. Hemifacial spasm: Clinical and electrophysiologic observations. Neurology 1979;29:1261-72.
3. Auger RG, Piegguess DG, Lawes ER Jr, Miller RH. Microvascular decompression of the facial nerve for hemifacial spasm: Clinical and electrophysiologic observations. Neurology 1981;31:346-50.
4. Auger RG, Whisnant JP. Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984. Arch Neurol 1990;47:1233-4.
5. Bandini F, Mazzella L. Gabapentin as treatment for hemifacial spasm. Eur Neurol 1999;42:49-51.
6. Barker FG 2nd, Jannetta PJ, Missonette DJ, Shields PT, Larkins MV, Jho HD. Microvascular decompression for hemifacial spasm. J Neurol 1995;82:201-10.
7. Carter JB, Patinely GJ, Jr, Jannetto E, McCrory JA 3rd, Boniuk M. Familial hemifacial spasm. Arch Ophthalmo1 1990;108:249-50.
8. Cook BR, Jannetta PJ. Tic convulsif. Results in 11 cases treated with microvascular decompression of the fifth and seventh cranial nerves. J Neurol 1984;61:949-51.
9. Cushing H. The major trigeminal neuralgias and their surgical treatment based on experiences with 332 Gasserian operations. Am J Med Sci 1920;160:157-84.
10. Deeb Z, Jannetta PJ, Rosenbaum AE, Kerber CW, Drayer BP. Tortuous vertebrobasilar arteries causing cranial nerve syndromes: Screening by computed tomography. J Comput Assist Tomogr 1979;3:774-8.
11. Dige K, Corbett J. Hemifacial spasm: Differential diagnosis, mechanism, and treatment. Adv Neurol 1988;49:151-76
12. Fabinyi GC, Adams CB. Hemifacial spasm: Treatment by posterior fossa surgery. J Neurol Neurosurg Psychiatry 1978;41:829-33.
13. Fairholm D, Wu JM, Liu KN. Hemifacial spasm: Results of microvascular relocation. Can J Neurol Sci 1983;10:187-91.
14. Friedman A, Janrozik Z, Bojakowski J. Familial hemifacial spasm. Mov Disord 1989;4:213-8.
15. Gardner WJ. Concerning the mechanism of trigeminal neuralgia and hemifacial spasm. J Neurol 1962;19:947-58.
16. Herzberg L. Management of hemifacial spasm with clonazepam. Neurology 1985;35:1676-7.
17. Higashi S, Yamashita J, Yamamoto Y, Izumi K. Hemifacial spasm associated with a cerebellopontine angle arachnoid cyst in a young adult. Surg Neurol 1992;37:289-92.
18. Hjorth RJ, Willson RG. The electromyogram in facial myokymia and hemifacial spasm. J Neurol Sci 1973;20:117-26.
19. House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg 1985;93:146-7.
20. Huang CI, Chen IH, Lee LS. Microvascular decompression for hemifacial spasm: Analyses of operative findings and results in 310 patients. Neurosurgery 1992;30:53-6.
21. Illingworth RD, Porter DG, Jakubowski J. Hemifacial spasm: A prospective long-term follow-up of 83 cases treated by microvascular decompression at two neurosurgical centres in the United Kingdom. J Neurol Neurosurg Psychiatry 1996;60:72-7.
22. Ishikawa M, Nakanishi T, Takamiya Y, Namiki J. Delayed resolution of residual hemifacial spasm after microvascular decompression operations. Neurosurgery 2001;49:847-54.
23. Iwakuma T, Matsumoto A, Nakamura N. Hemifacial spasm. Comparison of three different operative procedures in 110 patients. J Neurol 1982;57:753-6.
24. Jannetta PJ. The cause of hemifacial spasm: Definitive microsurgical treatment at the brainstem in 31 patients. Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol 1975;80:199-22.
25. Jannetta PJ. Outcome after microvascular decompression for typical trigeminal neuralgia, hemifacial spasm, tinnitus, disabling positional vertigo, and glossopharyngeal neuralgia (honored guest lecture). Clin Neurosurg 1997;44:331-83.
26. Jannetta PJ. Typical or atypical hemifacial spasm. J Neurol 1998;89:346-7.
27. Jannetta PJ, Kassam A. Hemifacial spasm. J Neurol Neurosurg Psychiatry 1999;66:255-6.
28. Jho HD, Jannetta PJ. Hemifacial spasm in young people treated with microvascular decompression of the facial nerve. Neurosurgery 1987;20:765-70.
29. Kaye AH, Adams CB. Hemifacial spasm: A long term follow-up of patients treated by posterior fossa surgery and facial nerve wrapping. J Neurol Neurosurg Psychiatry 1981;44:1100-3.
30. Kim P, Fukushima T. Observations on synkinesis in patients with hemifacial spasm. Effect of microvascular decompression and etiological considerations. J Neurosurg 1984;60:821-7.
31. Kobata H, Kondo A, Kinuta Y, Iwasaki K, Nishioka T, Hasegawa K. Hemifacial spasm in childhood and adolescence. Neurosurgery 1995;36:710-4.
32. Kondo A. Follow-up results of microvascular decompression in trigeminal neuralgia and hemifacial spasm. Neurosurgery 1997;40:46-51.
33. Kraft SP, Lang AE. Cranial dystonia, blepharospasm and hemifacial spasm: Clinical features and treatment, including the use of botulinum toxin. Cmaj 1998;159:847-44.
34. Langston JW, Tharp BR. Infantile hemifacial spasm. Arch Neurol 1976;33:302-3.
35. Loeser JD, Chen J. Hemifacial spasm: Treatment by microsurgical facial nerve decompression. Neurosurgery 1983;13:141-6.
36. Lundberg PO, Westerberg CE. A hereditary neurological disease with facial spasm. J Neurol Sci 1969;8:85-100.
37. Magur R, Esslen E. Electromyographic study of reinnervated muscle and of hemifacial spasm. Ann J Phys Med 1959;38:79-86.
38. Mauriello JA, Allain J. Natural history of treatment of facial dyskinesias with botulinum toxin: A study of 50 consecutive patients over seven years. Br J Ophthalmol 1991;75:734-7.
39. Millan-Guerrero RO, Tene-Perez E, Trujillo-Hernandez B. Levedopa in hemifacial spasm. A therapeutic alternative. Gac Med Mex 2000;136:565-71.
40. Moller AR. Hemifacial spasm: Ephaptic transmission or hyperexcitability of the facial motor nucleus? Exp Neurol 1987;98:110-9.
41. Moller AR, Jannetta PJ. Hemifacial spasm: Microvascular decompression to treat hemifacial spasm: Long-term results for a consecutive series of 143 patients. Neurosurgery 2002;50:712-8.
42. Montagna P, Imbriaco A, Zucconi M, Liguori R, Cirignotta F, Lugaresi E. Hemifacial spasm in sleep. Neurology 1986;36:270-3.
43. Nagata S, Matsushima T, Fujiy K, Fukui M, Kuromatsu S, Hasegawa K. Hemifacial spasm due to tumor, aneurysm, or arteriovenous malformation. Surg Neurol 1992;38:204-9.
44. Neary D, Dohrn D. Hemifacial spasm secondary to vascular compression of the facial nerve. Cleve Clin Q 1974;41:205-14.
45. Nielsen V, K. Electrophysiology of the facial nerve: In hemifacial spasm: Ectopic/ephaptic excitation. Muscle Nerve 1985;8:545-55.
46. Revuelta-Gutierrez R, Vales-Hidalgo LO, Arvizu-Saldana E, Hinojosa-Gonzalez R, Reyes-Moreno I. Microvascular decompression for hemifacial spasm. Ten years of experience. Cir Clin 2003:71:5-10.
47. Revuelta Gutierrez R, Soto-Hernandez JL, Suaste-Cueto R, Ramos-Peek J. Transient hemifacial spasm associated with subarachnoid brainstem cisternosis: A case report. Neurosurg Rev 1998;21:167-70.
48. Rhoton AL Jr. Microsurgical neurovascular decompression for trigeminal neuralgia and hemifacial spasm. J Fla Med Assoc 1978;65:425-8.
49. Rushworth RG, Smith SF. Trigeminal neuralgia and hemifacial spasm: Treatment by microvascular decompression. Med J Aust 1982;1:424-6.
50. Saito S, Moller AR. Chronic electrical stimulation of the facial nerve causes loss of facial nerve hyperactivity. Neurol Res 1993;15:225-31.
51. Samii M, Gunther T, Iaconetta G, Muehleng M, Yorkipic P, Samii A. Microvascular decompression to treat hemifacial spasm: A single-fiber EMG study. Muscle Nerve 1989;12:690-4.
52. Sanders DB. Ephaptic transmission in hemifacial spasm. Int J Neurosci 1987;33:261-4.
53. Shin JC, Chung UH, Kim YC, Park CJ. Prospective study of microvascular decompression in hemifacial spasm. Neurosurgery 1997;40:712-8.
54. Taylor JD, Kraft SP, Kazdan MS, Flanders M, Cadera W, Orton RB. Treatment of hemifacial spasm and hemifacial spasm with botulinum A toxin: A Canadian multicentre study. Can J Ophthalmol 1991;26:133-8.
55. Telisch F, Grobman LB, Schermata WA, Apple M, Ayar R. Hemifacial spasm. Occurrence in multiple sclerosis. Arch Otolaryngol Head Neck Surg 1991;117:554-6.
56. Vermeersch P, Petit H, Marion MH, Montagne B. Hemifacial spasm due to pontine infarction. J Neurosurg 1991;74:21018.
57. Westra I, Drummond GT. Occult pontine glioma in a patient with hemifacial spasm. Can J Ophthalmol 1991;26:148-51.
58. Wilkins RH. Hemifacial spasm: A review. Surg Neurol 1991;36:251-77.
59. Wilson CB, Yorke C, Prioleau G. Microvascular Vascular Decompression for Trigeminal Neuralgia and Hemifacial Spasm. West J Med 1980;132:481-7.
60. Wolten HW, Williams HL, Lambert EH. An attempt to relieve hemifacial spasm by neurolysis of the facial nerve; a report of two cases of hemifacial spasm with reflections on the nature of the spasm, the contracture and mass movement. Proc Staff Meet Mayo Clin 1951;26:236-40.